Background And Aim: Autologous erythrocytes can be used as carriers of drugs, owing to the ability of their membrane to be opened and resealed under appropriate conditions. In this pilot uncontrolled study, we investigated efficacy and safety of dexamethasone-encapsulated erythrocytes in steroid-dependent IBD patients.
Materials And Methods: Ten patients (5 with ulcerative colitis and 5 with Crohn's disease) with steroid dependency ranging from 8 to 60 months were studied. Seven of them were in clinical remission, and the remaining three had mild activity. Eight patients were also under azathioprine or 6-MP for at least 6 months (range 6-24 months), while another two patients were intolerant to both drugs. Fifty milliliters of blood were drawn from each subject; dexamethasone 21-Phosphate (Dex 21-P) was encapsulated into erythrocytes by means of specially designed equipment, and drug-loaded erythrocytes were infused into original donors. The procedure was repeated after 4 and 8 wk, and patients were instructed to withdraw corticosteroids.
Results: A mean dose of 5.5+/-2.4 mg Dex 21-P was loaded in the erythrocytes at each treatment. Following re-infusion of loaded erythrocytes, plasma Dexamethasone (Dex) concentrations were detected after as long as 28 days. Steroids were completely withdrawn by the second month. After the third infusion, all patients, including the three with mild active disease, were in clinical remission. ESR levels dropped from 47+/-27 at baseline to 27+/-16 mm/h (p<0.02), and CRP levels from 1.6+/-1.3 to 0.6+/-0.5 mg/dl (p<0.02). After a mean follow-up of 12+/-3 months, six patients relapsed, and the remaining four patients remained in remission. Pre-existing steroid-related adverse effects disappeared during the follow-up.
Conclusions: Loading of Dex 21-P in autologous erythrocytes is feasible and safe. The very low dose of Dex released in blood stream was able to maintain patients in clinical remission and allowed steroids withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1572-0241.2005.41412.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
Aliment Pharmacol Ther
September 2024
Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Background: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines.
Aims: To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD.
Methods: We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023.
Management of proctitis in ulcerative colitis and the place of biological therapies.
Expert Opin Biol Ther
June 2024
IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Introduction: Approximately 20-30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms.
Areas Covered: PubMed was searched up to March 2024 to identify relevant studies on UP.
Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
Crohns Colitis 360
April 2024
Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Article Synopsis
- A study was conducted in Brazil to evaluate the effectiveness and safety of ustekinumab (UST) in treating ulcerative colitis (UC), a condition with limited real-world data in Latin America.
- The research included 50 patients with moderate-to-severe UC, focusing on their clinical and endoscopic remission after one year of UST treatment; 50% achieved clinical remission, while 36% achieved endoscopic remission.
- The safety profile revealed that 20% of patients were hospitalized and 18% discontinued the drug mainly due to lack of effectiveness, but the treatment persistence rate at 24 months was 73.7%.
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice.
Indian J Gastroenterol
February 2024
Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Mindspace Road, Gachibowli, Hyderabad, 500 032, India.
Rising number of inflammatory bowel disease (IBD) cases in developing countries necessitate clear guidance for clinicians for the appropriate use of advanced therapies. An expert consensus document was generated to guide the usage of tofacitinib, a Janus kinase inhibitor, in ulcerative colitis. Tofacitinib is a useful agent for the induction and maintenance of remission in ulcerative colitis.
View Article and Find Full Text PDFFactors associated with corticosteroid use in Crohn's disease and ulcerative colitis patients in Israel: A multicenter cross-sectional study.
Dig Liver Dis
May 2024
Division of Gastroenterology, Rabin Medical Center, Petach Tikva, Israel; School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address:
Background: We examined corticosteroid use among Israeli patients with Inflammatory Bowel Disease (IBD), focusing on demographic, disease-related, and psychosocial factors. The objective was to contribute to the development of strategies minimizing corticosteroid dependence and improving patient outcomes, given the adverse effects associated with prolonged corticosteroid use.
Methods: A comprehensive analysis was conducted on data collected from adult IBD patients attending six gastroenterological outpatient clinics in Israel.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!